In this issue:
JADE DARE: more rapid relief from itch with abrocitinib vs dupilumab
Real-world effectiveness of newly initiated systemic therapy for AD
Probiotics supplements for the treatment of AD in adults
Progressive efficacy with 32-weeks of tralokinumab for moderate-to-severe AD
Pfizer mRNA vaccine protects against adverse COVID outcomes in patients with AD
Ruxolitinib cream safe and effective in maximal use trial
Dupilumab safe and efficacious for up to four years
Emollient use in neonatal period does not prevent AD
Quality of life benefits with attainment of higher threshold efficacy responses
Reduced incidence and severity of AD in the first year of life in infants born pre-term
Please login below to download this issue (PDF)